Information Provided By: 
Fly News Breaks for February 20, 2020
HCM
Feb 20, 2020 | 05:03 EDT
Goldman Sachs analyst Paul Choi initiated coverage of Hutchison China MediTech with a Buy rating and $38 price target. The company is on the cusp of a transition that will drive "significant value accretion" over the near-term with key milestones expected in 2020 and 2021, Choi tells investors in a research note. Global partnerships validate the quality of Hutchison's discovery engine, but increasing independence will shape the trajectory from here, he adds.
News For HCM From the Last 2 Days
There are no results for your query HCM
